말단비대증 시장 규모는 향후 몇 년 동안 빠르게 성장할 것으로 예상되며, 2029년까지 연평균 17.6%의 성장률로 49억 2,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 첨단 거대종양 치료제 연구개발 활동에 대한 투자, 스크리닝 프로그램 증가, 의료비 지출 증가, 최소침습적 치료 옵션에 대한 수요 증가 등에 기인합니다. 예측 기간의 주요 동향으로는 말단비대증에 대한 혁신적인 치료, 말단비대증 표적 치료제 개발, 강력한 의약품 파이프라인, 치료 옵션의 발전, 고도의 맞춤형 의료 등이 있습니다.
당뇨병과 같은 호르몬 질환의 유병률 증가는 말단비대증 시장의 성장을 촉진할 것으로 예상됩니다. 호르몬 질환(내분비 질환)은 내분비계 기능 장애로 인해 발생하며, 그 중 당뇨병은 가장 흔하고 영향력이 큰 질환입니다. 말단비대증 및 기타 내분비 질환은 성장호르몬이나 코티솔과 같은 특정 호르몬의 과다 분비로 인해 발생합니다. 또한, 성장호르몬 수치의 증가는 인슐린 생산에 영향을 미쳐 말단비대증 환자의 약 50%에서 인슐린 저항성 또는 제 2형 당뇨병을 유발할 수 있습니다. 예를 들어, 2024년 3월 영국 Office for Health Improvement and Disparities의 데이터에 따르면, 2022년 3월과 2023년 3월 사이에 권장되는 8가지 치료 과정을 모두 완료한 1형 당뇨병 환자의 비율은 22% 증가했고, 제2형 당뇨병은 21% 증가했습니다. HbA1c 목표치 달성률은 37.9%로 전국 당뇨병 감사(NDA) 보고에서 사상 최고치를 기록했습니다. 그 결과, 호르몬 질환의 유병률 증가는 말단비대증 시장을 발전시키는 중요한 요인으로 작용하고 있습니다.
유전자 이상 유병률의 증가는 향후 말단 거대증 시장의 미래 확장의 주요 촉진요인이 될 것으로 예상됩니다. 유전자 이상은 종종 유전자 결함 또는 유전자 장애로 알려져 있으며, 개인의 유전자 DNA 염기서열에 나타나는 변화 또는 돌연변이를 포함하며, 비정형적인 특징, 기능 및 특성을 초래할 수 있습니다. 뇌하수체에서 성장호르몬(GH)의 과잉 생산을 특징으로 하는 질환인 말단비대증은 종종 비암성 선종과 관련이 있으며, 이는 산발적으로 발생하기도 하고 특정 유전자 이상과 관련이 있을 수 있습니다. 예를 들어, 2022년 2월 현재 스위스에 본부를 둔 정부 간 기구인 세계보건기구(WHO)의 데이터에 따르면, 선천성 기형은 매년 생후 28일 이내에 24만 명의 신생아 사망에 기여하고 있습니다. 또한, 생후 1개월에서 5세까지 17만 명의 아이들이 심장병, 신경관 결손증, 다운증후군 등 선천성 기형으로 인해 목숨을 잃습니다. 이에 따라 유전자 이상 발생률이 증가하고 있으며, 선천성 거대증 시장을 발전시킬 준비가 되어 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계 말단비대증 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인, 억제요인)
- 최종 이용 산업 분석
- 세계의 말단비대증 시장 : 성장률 분석
- 세계의 말단비대증 시장 실적 : 규모와 성장, 2019-2024
- 세계의 말단비대증 시장 예측 : 규모와 성장, 2024-2029, 2034F
- 세계 말단비대증 전체 시장(TAM)
제6장 시장 세분화
- 세계의 말단비대증 시장 : 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 이소성 말단비대증
- 성장호르몬에 의한 말단비대증
- 세계의 말단비대증 시장 : 진단별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- GH와 IGF-I 측정
- 성장호르몬 억제 시험
- 이미징
- 기타 진단
- 세계의 말단비대증 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 경구
- 비경구
- 기타 투여 경로
- 세계의 말단비대증 시장 : 치료별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 약
- 소마토스타틴 유사체
- 도파민 작용제
- 성장호르몬 길항제
- 수술
- 방사선
- 기타 치료법
- 세계의 말단비대증 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 병원
- 전문 클리닉
- 홈케어
- 기타 최종사용자
- 세계의 말단비대증 시장, 이소성 말단비대증 종류별 분류, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 종양 유발 이소성 말단비대증
- 비종양성 이소성 말단비대증
- 세계의 말단비대증 시장, 성장호르몬에 의한 말단비대증 하위 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 1차 성장호르몬 과잉
- 2차 성장호르몬 과잉
제7장 지역별·국가별 분석
- 세계의 말단비대증 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 세계의 말단비대증 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- 말단비대증 시장 : 경쟁 구도
- 말단비대증 시장 : 기업 개요
- Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
- Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
- AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- Bayer AG Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
- Novartis AG
- Sanofi S.A.
- AstraZeneca plc
- GlaxoSmithKline plc
- Eli Lilly and Company
- Gilead Sciences Inc.
- Boehringer Ingelheim International GmbH.
- Amgen Inc.
- Allergan Inc.
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Ipsen Pharma S.A.
- Hikma Pharmaceuticals PLC
- Lupin Ltd.
- Recordati S.p.A.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
- 말단비대증 시장 2029 : 새로운 기회를 제공하는 국가
- 말단비대증 시장 2029 : 새로운 기회를 제공하는 부문
- 말단비대증 시장 2029 : 성장 전략
제36장 부록
ksm
Acromegaly is an infrequent hormonal disorder stemming from the excessive production of growth hormone by the pituitary gland, a small structure situated at the base of the brain. This surplus of growth hormone triggers the enlargement and thickening of bones and tissues, predominantly affecting areas such as the hands, feet, and face.
The primary classifications of acromegaly encompass ectopic acromegaly and acromegaly due to growth hormone. Ectopic acromegaly is a rare medical condition characterized by the overproduction of growth hormone (GH) originating from a source outside the pituitary gland. The diagnostic methods employed include GH and IGF-I measurement, growth hormone suppression tests, imaging, and various others, which can be administered through diverse routes, including oral, parenteral, and others. Treatment options are available, ranging from medications, somatostatin analogues, dopamine agonists, and growth hormone antagonists to surgical procedures, radiation therapy, and other approaches. These treatments find application across various end users, including hospitals, specialty clinics, homecare settings, and others.
The acromegaly market research report is one of a series of new reports from The Business Research Company that provides acromegaly market statistics, including acromegaly industry global market size, regional shares, competitors with an acromegaly market share, detailed acromegaly market segments, market trends and opportunities and any further data you may need to thrive in the acromegaly industry. This acromegaly market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The acromegaly market size has grown rapidly in recent years. It will grow from $2.15 billion in 2024 to $2.57 billion in 2025 at a compound annual growth rate (CAGR) of 19.6%. The growth in the historic period can be attributed to increasing prevalence of acromegaly therapeutics, growing awareness about acromegaly, government initiatives, demand for effective treatments.
The acromegaly market size is expected to see rapid growth in the next few years. It will grow to $4.92 billion in 2029 at a compound annual growth rate (CAGR) of 17.6%. The growth in the forecast period can be attributed to investments in research and development activities for acromegaly treatments, growing number of screening programs, rising healthcare spending, increasing demand for minimally invasive treatment options. Major trends in the forecast period include innovative treatments for acromegaly, development of targeted therapies for acromegaly, strong pipeline of drugs, advancements in treatment options, advanced personalized medicine.
The rising incidence of hormonal diseases, such as diabetes, is expected to drive growth in the acromegaly market. Hormonal diseases, or endocrine disorders, arise from dysfunctions within the endocrine system, with diabetes being among the most common and impactful. Acromegaly and other endocrine disorders can occur due to the excessive production of certain hormones, like growth hormone or cortisol. Additionally, elevated growth hormone levels can affect insulin production, leading to insulin resistance or type 2 diabetes mellitus in approximately 50% of individuals with acromegaly. For example, in March 2024, data from the UK's Office for Health Improvement and Disparities revealed that between March 2022 and March 2023, the percentage of type 1 diabetes patients completing all eight recommended care processes increased by 22%, and for type 2 diabetes, by 21%. The proportion achieving target HbA1c levels reached 37.9%, the highest ever reported by the National Diabetes Audit (NDA). Consequently, the growing prevalence of hormonal diseases is a key factor propelling the acromegaly market forward.
The escalating prevalence of genetic abnormalities is poised to be a key driver for the future expansion of the acromegaly market. Genetic abnormalities, often known as genetic defects or genetic disorders, encompass alterations or mutations that manifest in the DNA sequence of an individual's genes and can lead to atypical features, functions, or characteristics. Acromegaly, a condition characterized by the overproduction of growth hormone (GH) by the pituitary gland, is frequently associated with noncancerous adenomas, which can occur sporadically or be linked to specific genetic abnormalities. For instance, as of February 2022, data from the World Health Organization (WHO), a Switzerland-based intergovernmental organization, indicated that congenital abnormalities contribute to the mortality of 240,000 newborns within the first 28 days of life annually. Additionally, an extra 170,000 children aged between 1 month and 5 years lose their lives due to congenital abnormalities, encompassing conditions like heart defects, neural tube defects, and Down syndrome. Consequently, the rising incidence of genetic abnormalities is poised to propel the acromegaly market forward.
Leading companies in the acromegaly market are prioritizing the development of innovative products and solutions, such as generic lanreotide, to expand treatment options and improve patient outcomes. Generic lanreotide is an unbranded version of the medication used to treat acromegaly and certain neuroendocrine tumors. As a somatostatin analogue, it helps reduce growth hormone secretion, making effective treatment more accessible for patients. For example, in October 2024, Teva Pharmaceutical Industries Ltd., an Israel-based company specializing in generic drugs, launched the first generic version of Sandostatin LAR Depot in the U.S. This injectable suspension, octreotide acetate, is indicated for treating acromegaly and severe diarrhea linked to carcinoid syndrome, providing essential therapy access to patients in need.
In July 2024, AstraZeneca plc, a UK-based multinational pharmaceutical and biotechnology company, acquired Amolyt Pharma for $1.05 billion. This acquisition enhances AstraZeneca's pipeline in rare disease treatments, particularly in endocrine and metabolic disorders, as Amolyt's innovative therapies complement the company's commitment to advancing patient care and addressing unmet medical needs. Amolyt Pharma, a France-based clinical-stage biopharmaceutical company, specializes in developing treatments for rare endocrine diseases, including eneboparatide for hypoparathyroidism and AZP-3813, a peptide antagonist for acromegaly.
Major companies operating in the acromegaly market are Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH., Amgen Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Ipsen Pharma S.A., Hikma Pharmaceuticals PLC, Lupin Ltd., Recordati S.p.A., Ionis Pharmaceuticals Inc., Amryt Pharma plc, Strongbridge Biopharma PLC, Aquestive Therapeutics Inc., Peptron Inc., Crinetics Pharmaceuticals, Chiasma Inc.
North America was the largest region in the acromegaly market in 2024. The regions covered in acromegaly report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the acromegaly market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.
The acromegaly market consists of revenues earned by entities by providing hormone replacement therapy, pituitary radiotherapy and lifestyle modifications. The market value includes the value of related goods sold by the service provider or included within the service offering. The acromegaly market also includes sales of octreotide, lanreotide and somavert. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Acromegaly Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on acromegaly market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for acromegaly ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acromegaly market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type: Ectopic Acromegaly; Acromegaly Due To Growth Hormone
- 2) By Diagnosis: GH And IGF-I Measurement; Growth Hormone Suppression Test; Imaging; Other Diagnosis
- 3) By Route Of Administration: Oral; Parenteral; Other Route Of Administrations
- 4) By Treatment: Medication; Somatostatin analogues; Dopamine Agonists; Growth Hormone Antagonist; Surgery; Radiation; Other Treatments
- 5) By End Users: Hospitals; Specialty Clinics; Homecare; Other End Users
- Subsegments:
- 1) By Ectopic Acromegaly: Tumor-Induced Ectopic Acromegaly; Non-Tumor-Induced Ectopic Acromegaly
- 2) By Acromegaly Due To Growth Hormone: Primary Growth Hormone Excess; Secondary Growth Hormone Excess
- Companies Mentioned: Pfizer Inc.; Johnson & Johnson Private Limited; Merck & Co Inc.; AbbVie Inc.; Bayer AG
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Acromegaly Market Characteristics
3. Acromegaly Market Trends And Strategies
4. Acromegaly Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
5. Global Acromegaly Growth Analysis And Strategic Analysis Framework
- 5.1. Global Acromegaly PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Acromegaly Market Growth Rate Analysis
- 5.4. Global Acromegaly Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Acromegaly Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Acromegaly Total Addressable Market (TAM)
6. Acromegaly Market Segmentation
- 6.1. Global Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Ectopic Acromegaly
- Acromegaly Due To Growth Hormone
- 6.2. Global Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- GH And IGF-I Measurement
- Growth Hormone Suppression Test
- Imaging
- Other Diagnosis
- 6.3. Global Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Parenteral
- Other Route Of Administrations
- 6.4. Global Acromegaly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Medication
- Somatostatin analogues
- Dopamine Agonists
- Growth Hormone Antagonist
- Surgery
- Radiation
- Other Treatments
- 6.5. Global Acromegaly Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Specialty Clinics
- Homecare
- Other End Users
- 6.6. Global Acromegaly Market, Sub-Segmentation Of Ectopic Acromegaly, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Tumor-Induced Ectopic Acromegaly
- Non-Tumor-Induced Ectopic Acromegaly
- 6.7. Global Acromegaly Market, Sub-Segmentation Of Acromegaly Due To Growth Hormone, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Primary Growth Hormone Excess
- Secondary Growth Hormone Excess
7. Acromegaly Market Regional And Country Analysis
- 7.1. Global Acromegaly Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Acromegaly Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Acromegaly Market
- 8.1. Asia-Pacific Acromegaly Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Acromegaly Market
- 9.1. China Acromegaly Market Overview
- 9.2. China Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Acromegaly Market
- 10.1. India Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Acromegaly Market
- 11.1. Japan Acromegaly Market Overview
- 11.2. Japan Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Acromegaly Market
- 12.1. Australia Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Acromegaly Market
- 13.1. Indonesia Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Acromegaly Market
- 14.1. South Korea Acromegaly Market Overview
- 14.2. South Korea Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Acromegaly Market
- 15.1. Western Europe Acromegaly Market Overview
- 15.2. Western Europe Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Acromegaly Market
- 16.1. UK Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Acromegaly Market
- 17.1. Germany Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Acromegaly Market
- 18.1. France Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Acromegaly Market
- 19.1. Italy Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Acromegaly Market
- 20.1. Spain Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Acromegaly Market
- 21.1. Eastern Europe Acromegaly Market Overview
- 21.2. Eastern Europe Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Acromegaly Market
- 22.1. Russia Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Acromegaly Market
- 23.1. North America Acromegaly Market Overview
- 23.2. North America Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Acromegaly Market
- 24.1. USA Acromegaly Market Overview
- 24.2. USA Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Acromegaly Market
- 25.1. Canada Acromegaly Market Overview
- 25.2. Canada Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Acromegaly Market
- 26.1. South America Acromegaly Market Overview
- 26.2. South America Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Acromegaly Market
- 27.1. Brazil Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Acromegaly Market
- 28.1. Middle East Acromegaly Market Overview
- 28.2. Middle East Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Acromegaly Market
- 29.1. Africa Acromegaly Market Overview
- 29.2. Africa Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Acromegaly Market Competitive Landscape And Company Profiles
- 30.1. Acromegaly Market Competitive Landscape
- 30.2. Acromegaly Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
31. Acromegaly Market Other Major And Innovative Companies
- 31.1. Novartis AG
- 31.2. Sanofi S.A.
- 31.3. AstraZeneca plc
- 31.4. GlaxoSmithKline plc
- 31.5. Eli Lilly and Company
- 31.6. Gilead Sciences Inc.
- 31.7. Boehringer Ingelheim International GmbH.
- 31.8. Amgen Inc.
- 31.9. Allergan Inc.
- 31.10. Teva Pharmaceutical Industries Ltd.
- 31.11. Mylan N.V.
- 31.12. Ipsen Pharma S.A.
- 31.13. Hikma Pharmaceuticals PLC
- 31.14. Lupin Ltd.
- 31.15. Recordati S.p.A.
32. Global Acromegaly Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Acromegaly Market
34. Recent Developments In The Acromegaly Market
35. Acromegaly Market High Potential Countries, Segments and Strategies
- 35.1 Acromegaly Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Acromegaly Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Acromegaly Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
